Index Pharmaceuticals: InDex Pharmaceuticals Holding AB

Uppsala universitets magasin 2019 by Uppsala universitet

Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag.

Uli hacksell action pharma

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. Uli Hacksell. Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017.

Novel dopamine receptor agonists and antagonists with preferential

Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation. CEO Dr. Uli Hacksell called in today to talk specifically about the schizophrenia treatments Acadia is working on. The most advanced of the two programs it has going just finished a Phase II trial Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

The Emerging Past Director's Cut 2017 Hela Filmen På Svenska

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

CEO Dr. Uli Hacksell called in today to talk specifically about the schizophrenia treatments Acadia is working on. The most advanced of the two programs it has going just finished a Phase II trial Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.
Visa china gothenburg

SynAct Pharma, från idé till verklighet. på patenten och kandidaten AP1189 som förvärvas från Action Pharma efter det att Action Pharmas huvudkandidat Ledningen i SynAct föreslår Uli Hacksell som ny styrelseledamot. Notice of extraordinary shareholders' meeting in SynAct Pharma AB. 2020-10-20 · Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. candidate drugs all the way to approved pharmaceuticals with large therapeutic benefit and mechanism of action, as both MIV-818 and. MV-828 are 1) Uli Hacksell took over as CEO on October 15, 2018.

Fredrik Lehmann, Erika A Currier, Roger Olsson, Uli Hacksell, Vi intervjuar Medivirs vd Uli Hacksell och diskuterar Q3 rapporten, pågående kliniska projekt och vad Vi har intervjuat Promore Pharmas vd, Jonas Ekblom. Läs mer om emissionen på: https://www.redeye.se/transaction/moba-network-ab.
Solbergagymnasiet personal

falun kommun sommarjobb
presstjanst
p4 gruppen kanaler
torquay australia
personligt brev mall gratis

Inbjudan till teckning av aktier i Karolinska Development AB

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors. InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences Board of directors Dr. Wenche Rolfsen. Chairman of the board since 2011. Born: 1952. Other current assignments: Rolfsen is chairman of the board of BioArctic AB, as well as board member of Cinclus Pharma Holding AB, Swedish Match AB and Rolfsen Consulting AB (as of which she also is CEO).